(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
10 September 2021 (10.09.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/178531 A1

(51) International Patent Classification:
A61K 31/426 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/US2021/020661

(22) International Filing Date:
03 March 2021 (03.03.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/984,765 03 March 2020 (03.03.2020) US
63/148,683 12 February 2021 (12.02.2021) US

(71) Applicant: **CYTEIR THERAPEUTICS, INC.** [US/US]; 128 Spring Street, Building A, Suite 510, Lexington, Massachusetts 02421 (US).

(72) Inventors: **O'SHEA, Thomas**; 5 Larch Road, Wellesley, Massachusetts 02482 (US). **RENSCHLER, Markus**; c/o Cyteir Therapeutics, Inc., 128 Spring Street, Building A, Suite 510, Lexington, Massachusetts 02421 (US). **BOWSER, Todd**; 88 Haggerty Road, Charlton, Massachusetts 01507 (US). **LAPIERRE, Jean-Marc**; 1 Alexandra Drive, Pelham, New Hampshire 03076 (US). **MILLS, Kevin**; 442 Old Harvard Rd, Boxborough, Massachusetts 01719 (US).


(74) Agent: **PAVAO, Matthew** et al.; 1299 Pennsylvania Ave., Suite 700, Washington, 20004 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


(54) Title: THE RAD51 INHIBITOR COMPOUND 67A (2301085-06-1) AT A SPECIFIC DOSAGE FOR TREATING CANCER

(57) Abstract: This application is directed to inhibitors of RAD51 represented by the following structural formula, and methods for its use, such as to treat cancer.



(I)

FIG. 5



Subject with relapsed/refractory DLBCL

WO 2021/178531 A1

[Continued on next page]

Published:
— *with international search report (Art. 21(3))*